These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1566635)

  • 1. [The effect of oral ovulation inhibiting (mono-, bi- and triphase) contraceptives and of Continuin and Postinor on proteo- and steroid hormones].
    Farkas M
    Acta Pharm Hung; 1992; 62(1-2):17-30. PubMed ID: 1566635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacologic study of Tri-Regol tablets (new oral triphase contraceptives)].
    Farkas M; Kovács L; Tasiné Tóth E
    Acta Pharm Hung; 1990 May; 60(2-3):85-99. PubMed ID: 2117333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
    Gitsch E; Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pharmacological examination of Postinor (0.75 mg d-norgestrel).
    Farkas M; Apró G; Sas M
    Ther Hung; 1981; 29(1):22-30. PubMed ID: 7188237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinico-laboratory research on the pharmacodynamic characteristics of Rigevidon].
    Korkhov VV; Nikanorova SA
    Farmakol Toksikol; 1987; 50(1):97-100. PubMed ID: 3556564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with hormonal contraceptives.
    Kulakov VI
    Acta Med Hung; 1986; 43(2):93-6. PubMed ID: 3588163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and endocrine effects of long-term hormonal contraception.
    Balogh A
    Acta Med Hung; 1986; 43(2):97-102. PubMed ID: 3588164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
    Aden U; Jung-Hoffmann C; Kuhl H
    Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopharmacological examination of Anteovin.
    Farkas M; Szigethy A; Sas M
    Ther Hung; 1987; 35(1):14-8. PubMed ID: 3438859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinico-pharmacological characteristics of anteovin].
    Nikanorova SA; Kononova ES; Korkhov VV; Potin VV; Svechnikova FA; Boĭkova VV
    Farmakol Toksikol; 1991; 54(1):30-1. PubMed ID: 1860494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observations with a tri-phasic oral contraceptive (Tri-Regol) in everyday clinical practice.
    Kovács I; Novák K; Pomázi L; Hammersberg E
    Ther Hung; 1992; 40(2):86-9. PubMed ID: 1462283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
    Kuhl H; Gahn G; Romberg G; März W; Taubert HD
    Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R; Reinilä M; Kivinén S
    Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.